Glazer Capital LLC’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Glazer Capital LLC’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,283,910	Closed	-$23.1M	–	548
2022 Q4	$23.1M	Sell	2,283,910 -1,090	-0%	-$10.9K	0.6%	58
2022 Q3	$22.7M	Buy	2,285,000 +1,648,917	+259%	+$16.3M	0.42%	66
2022 Q2	$6.3M	Buy	+636,083	New	+$6.24M	0.16%	207
2022 Q1	–	Sell	-110,599	Closed	-$1.09M	–	824
2021 Q4	$1.09M	Buy	+110,599	New	+$1.09M	0.03%	395

Glazer Capital LLC's BIOT Position: Q1 2023 in Review

Glazer Capital LLC sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 2,283,910 shares — an estimated $23.1M sold.

Glazer Capital LLC first reported a position in BIOT in Q4 2021 and held it in 4 quarters. The position peaked at $23.1M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Glazer Capital LLC reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Glazer Capital LLC sold 2,283,910 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $23.1M.
Glazer Capital LLC first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 4 quarters.
Glazer Capital LLC's Biotech Acquisition Company Class A Ordinary Shares position peaked at $23.1M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Glazer Capital LLC's 13F filing for Q1 2023, filed 15 May 2023.